Brief: Alexion, Astrazeneca Rare Disease To Acquire Logicbio Therapeutics To Accelerate Growth In Genomic Medicine
03/10/2022 12:16
Oct 3 (Reuters) - LogicBio Therapeutics Inc LOGC.O :
* ALEXION, ASTRAZENECA RARE DISEASE TO ACQUIRE LOGICBIO®
THERAPEUTICS TO ACCELERATE GROWTH IN GENOMIC MEDICINE
* LOGICBIO THERAPEUTICS INC - ALEXION, THROUGH A SUBSIDIARY,
WILL
INITIATE A CASH TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES
OF LOGICBIO FOR $2.07 PER SHARE
* LOGICBIO THERAPEUTICS INC - BOTH BOARDS HAVE UNANIMOUSLY
APPROVED TRANSACTION
* LOGICBIO THERAPEUTICS INC - ALEXION PLANS TO CLOSE DEAL IN
FOUR
TO SIX WEEKS
Source text for Eikon: ID:nPn7pxCN5a
Further company coverage: LOGC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ContextLogic Holdings
See all newsContextLogic Holdings Q2 revenue flat as higher prices offset lower volumes
Brief: ContextLogic Holdings Q2 Adjusted EBITDA USD 10.8 Million
ContextLogic Holdings Q1 net income jumps on tax benefit
Brief: ContextLogic Holdings Q1 Net Income USD 17 Million
Brief: Contextlogic To Acquire US Salt From Emerald Lake In $907.5 Million Transaction, Creating New Business Ownership Platform In Partnership With Abrams Capital And BC Partners Credit